Dickon Hayne accepted the BJUI Global Prize for 2023 for the Pain-Free TRUS B article that
featured in BJUI in 2022, at the USANZ meeting in Brisbane on behalf of the Australian and
New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) on Sunday 26 February.
“‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of
methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal
ultrasonography-guided prostate biopsy.”
This prize is given to an author/ authors outside of America & Europe selected by a BJUI
panel as the best paper in terms of quality and potential impact on practice.
The study was initially a concept put forward by Jeremy Grummet at a concept session
during an ANZUP Annual Scientific Meeting in 2015. At the time we thought the idea was
simple, but great, so ANZUP applied and was successful in receiving a Cancer Australia
Subsequently site Principal Investigators Nick Buchan and Dickon Hayne recruited many of
the trial participants, and Dickon was the lead author on the paper and accepted the award
on behalf of the study team.
“Pain-Free TRUS B was a genuinely high quality randomised clinical controlled trial and
represents a fantastic trans-Tasman effort and a real win for ANZUP,” says Dickon Hayne.
The study was conducted between January 2016 and November 2019 and enrolled 420
people across Australian and New Zealand.
Outcomes of the trial were promising and improvements were seen in patient-reported
discomfort, overall experience, and willingness to undergo repeat biopsies.
This is a great achievement, for a simple, yet innovative idea that helped improve the
patient experience of cancer care.
Media Contact – ANZUP:
Nicole Tankard, Internal Communications & Media
Mobile: +61 402 202 042, Email: firstname.lastname@example.org
ANZUP is the leading cancer-cooperative clinical trials group that brings together all of the
professional disciplines and groups involved in researching and treating urogenital cancers
and conduct high quality clinical research. ANZUP identifies gaps in evidence and areas of
clinical need, collaborates with the best clinicians and researchers in GU cancer and
communicates frequently and effectively with the broader community along the
way. ANZUP receives valuable infrastructure support from the Australian Government
through Cancer Australia.